Journal of the American College of Surgeons
Volume 210, Issue 2 , Pages 199-204 , February 2010

Safety and Immunogenicity Observations Pooled from Eight Clinical Trials of Recombinant Human Thrombin

  • Jeffrey L. Ballard, MD, FACS

      Affiliations

    • Vascular and Interventional Specialists of Orange County, Inc, Orange, CA
    • ,
  • Fred A. Weaver, MD, FACS

      Affiliations

    • USC CardioVascular Thoracic Institute, USC University Hospital, Keck School of Medicine, University of Southern California, Los Angeles, CA
    • ,
  • Neil K. Singla, MD

      Affiliations

    • Lotus Clinical Research, Huntington Memorial Hospital, Pasadena, CA
    • ,
  • William C. Chapman, MD, FACS

      Affiliations

    • Department of Surgery, Washington University in St Louis School of Medicine, St Louis MO
    • ,
  • W. Allan Alexander, MD

      Affiliations

    • ZymoGenetics, Inc, Seattle, WA
    • Corresponding Author InformationCorrespondence address: W Allan Alexander, MD, ZymoGenetics, Inc, 1201 Eastlake Ave E, Seattle, WA 98102

Received 24 July 2009 ,Accepted 29 September 2009.

References 

  1. ZymoGenetics, Inc.. Prescribing information: RECOTHROM. 2009;
  2. Meehan WP, Bolton MG. Recombinant human thrombin: demonstration of efficacy in models of surgical bleeding. [abstract P54] J Surg Res. 2004;121:323
  3. Chapman WC, Lockstadt H, Singla N, et al. Phase 2, randomized, double-blind, placebo-controlled, multicenter clinical evaluation of recombinant human thrombin in multiple surgical indications. J Thromb Haemost. 2006;4:2083–2085
  4. Greenhalgh DG, Gamelli RL, Collins J, et al. Recombinant thrombin: safety and immunogenicity in burn wound excision and grafting. J Burn Care Res. 2009;30:371–379
  5. Chapman WC, Singla N, Genyk Y, et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg. 2007;205:256–265
  6. Weaver FA, Lew W, Granke K, et al. A comparison of recombinant thrombin to bovine thrombin as a hemostatic ancillary in patients undergoing peripheral arterial bypass and arteriovenous graft procedures. J Vasc Surg. 2008;47:1266–1273
  7. Singla NK, Ballard JL, Moneta G, et al. A phase 3b, open-label, single-group immunogenicity and safety study of topical recombinant thrombin in surgical hemostasis. J Am Coll Surg. 2009;1:68–74
  8. King Pharmaceuticals, Inc.. Prescribing information: Thrombin-JMI. 2007;
  9. Heffernan JK, Ponce RA, Zuckerman LA, et al. Preclinical safety of recombinant human thrombin. Regul Toxicol Pharmacol. 2007;47:48–58
  10. Anderson CD, Bowman LJ, Chapman WC. Topical use of recombinant human thrombin for operative hemostasis. Expert Opin Biol Ther. 2009;9:133–137
  11. Kessler CM, Ortel TL. Recent developments in topical thrombins. Thromb Haemost. 2009;102:15–24
  12. OMRIX Biopharmaceuticals LtdEthicon, Inc.. (J&J Wound Management) Prescribing information: Evithrom. 2007;
  13. Dorion RP, Hamati HF, Landis B, et al. Risk and clinical significance of developing antibodies induced by topical thrombin preparations. Arch Pathol Lab Med. 1998;122:887–894
  14. Ortel TL, Mercer MC, Thames EH, et al. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg. 2001;233:88–96
  15. Lawson JH, Lynn KA, Vanmatre RM, et al. Antihuman factor V antibodies after use of relatively pure bovine thrombin. Ann Thorac Surg. 2005;79:1037–1038
  16. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant. 2005;20(Suppl 6):vi3–vi9
  17. Koren E, Zuckerman LA, Mire-Sluis AR. Immune responses to therapeutic proteins in humans–clinical significance, assessment and prediction. Curr Pharm Biotechnol. 2002;3:349–360
  18. Schellekens H, Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol. 2004;251(Suppl 2):II4–II9
  19. Kromminga A, Schellekens H. Antibodies against erythropoietin and other protein-based therapeutics: an overview. Ann NY Acad Sci. 2005;1050:257–265
  20. Purcell RT, Lockey RF. Immunologic responses to therapeutic biologic agents. J Investig Allergol Clin Immunol. 2008;18:335–342
  21. Koren E, Smith HW, Shores E, et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods. 2008;333:1–9
  22. International Conference on Harmonisation (ICH) E2A guideline on clinical safety data management, definitions and standards for expedited reporting. http://www.ich.org/cache/compo/276-254-1.htmlAccessed November 11, 2009
  23. Ballantyne JC, Loach AB, Carr DB. Itching after epidural and spinal opiates. Pain. 1988;33:149–160
  24. Bendtzen K, Hansen MB, Ross C, Svenson M. High-avidity autoantibodies to cytokines. Immunol Today. 1998;19:209–211
  25. Lutz HU, Binder CJ, Kaveri S. Naturally occurring auto-antibodies in homeostasis and disease. Trends Immunol. 2009;30:43–51
  26. Laricchia-Robbio L, Moscato S, Genua A, et al. Naturally occurring and therapy-induced antibodies to human granulocyte colony-stimulating factor (G-CSF) in human serum. J Cell Physiol. 1997;173:219–226
  27. Ross C, Hansen MB, Schyberg T, Berg K. Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN-alpha 2b and human IFN-gamma in healthy blood donors. Clin Exp Immunol. 1990;82:57–62
  28. Elkon K, Casali P. Nature and functions of autoantibodies. Nat Clin Pract Rheumatol. 2008;4:491–498

 The clinical trials were supported in full by ZymoGenetics.

 Disclosure Information: Dr Alexander is a salaried employee and holds an ownership interest in ZymoGenetics, Inc, and Dr Weaver is a speaker who has received honoraria from ZymoGenetics, Inc. The other authors have nothing to disclose.

 ClinicalTrials.gov: NCT00491608, NCT00371215, NCT00245336.

PII: S1072-7515(09)01458-6

doi: 10.1016/j.jamcollsurg.2009.09.042

Journal of the American College of Surgeons
Volume 210, Issue 2 , Pages 199-204 , February 2010

Article Tools

* Image Usage & Resolution